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Background: RAD21 encodes a key component of the cohesin complex, and variants in RAD21 have 
been associated with Cornelia de Lange Syndrome (CdLS). Limited information on phenotypes 
attributable to RAD21 variants and genotype-phenotype relationships is currently published.  
Methods: We gathered a series of 49 individuals from 33 families with RAD21 alterations (40 unique 
intragenic sequence variants, 7 microdeletions), including 24 hitherto unpublished cases. We 
evaluated consequences of twelve intragenic variants by protein modelling and molecular dynamic 
studies.   
Results: Full clinical information was available for 29 individuals. Their phenotype is an attenuated 
CdLS phenotype compared to that caused by variants in NIPBL or SMC1A for facial morphology, limb 
anomalies, and especially for cognition and behavior. In the 20 individuals with limited clinical 
information, additional phenotypes include Mungan syndrome and holoprosencephaly, with or 
without CdLS characteristics. We describe several additional cases with phenotypes including 
sclerocornea, in which involvement of the RAD21 variant is uncertain. 
Variants were frequently familial, and genotype-phenotype analyses demonstrated striking 
interfamilial and intrafamilial variability.  
Conclusion: Careful phenotyping is essential in interpreting consequences of RAD21 variants, and 
protein modeling and dynamics can be helpful in determining pathogenicity. The current study 
should be helpful when counseling families with a RAD21 variation. 
Funding: RTC-2017-6494-1, RTI2018-094434-B-I00, European JPIAMR-VRI network “CONNECT”, FIS 









RAD21 (ENSG00000164754; OMIM *606462) is a key component of the cohesin complex and it forms 
a tri-partite ring together with SMC1A and SMC3 (Fig. 1 and Suppl. Fig. S1). The cohesin complex is a 
major modulator of chromosome structure, is involved in regulating chromosome segregation during 
mitosis, DNA repair and chromatin condensation, and plays an important role in gene transcription 
during interphase and cellular homeostasis 1-3. RAD21 has been implicated in additional processes 
including mediation of epigenetic silencing and induction of apoptosis 4,5. Variants in genes encoding 
various structural or functional components of the cohesin complex, including RAD21, SMC1A, SMC3, 
BRD4, STAG1/2, NIPBL, HDAC8, WAPL, ANKRD11 and in single individuals PDS5A and ESPL1, have 
been implicated in Cornelia de Lange Syndrome (CdLS) 6-9. RAD21 spans ~29 Kb and has 14 exons (13 
coding, 1 noncoding) that together encode a protein of 631 amino acids 10.  
RAD21 variants are found in a minority of CdLS patients. To date, nine missense variants and 
5 microdeletions have been reported in CdLS patients 9. CdLS is characterized by distinct facial 
features, growth delay, microcephaly, limb reduction defects, intellectual disability (ID) and 
behavioral problems, especially self-injurious behavior (SIB) and autism spectrum disorder (ASD) 9. 
RAD21 variants have also been associated with sclerocornea 11 and Mungan syndrome (OMIM 
#611376) 12,13, each in a single family in which no remarks on CdLS features were made in the report. 
Loss of function-variants in cohesin genes including RAD21 were found in individuals with 
holoprosencephaly of whom some demonstrated CdLS features as well 14. 
RAD21 is positioned on chromosome 8q24.11, between TRPS1 (Tricho-Rhino-Phalangeal 
syndrome type 1; OMIM *604386) and EXT1 (Multiple Exostoses type 1; OMIM *608177). Several 
microdeletions involving RAD21 encompass genes next to RAD21 (contiguous gene syndrome), 
complicating attribution to RAD21 of the phenotype 15-17. TRPS type 2 or Langer-Giedion syndrome 
(OMIM #150230) involves TPRS1, RAD21 and EXT1, and the facial phenotype is mainly determined by 
loss of TRPS1, whereas the bony abnormalities arise from loss of EXT1 18. 
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Based on the small case series of CdLS patients with RAD21 variants reported so far, face and 
limb manifestations of CdLS seem to be less pronounced compared to individuals with variants in the 
other cohesin complex genes, and the impact on cognitive functioning seems attenuated, without 
clear genotype-phenotype correlation 9,19. Here, we report on a case series of 49 patients from 33 
families with RAD21 alterations, including all previously published cases with sequence variants, 
most of which with updated clinical data. We included 24 hitherto unpublished cases. We present 
genotype data, evaluate pathogenicity of intragenic variants by a combination of phenotype, protein 
modelling, and molecular dynamic studies, and provide information on clinical phenotype, including 
cognitive and behavioral functioning, interfamilial and intrafamilial variability, and genotype-







We identified 219 cases with RAD21 variants, of which 49 patients from 33 families were included in 
this study (Table S1). We describe in Table S6 those excluded cases that still may be of interest such 
as published cases with involvement of other morbid genes 15-18,23, variants reported as variant of 
unknown significance (VUS) that remained with unknown significance subsequent to re-evaluation, 
and cases for whom the relationship between phenotype and RAD21 variant could not be confirmed 
11,14.  
 The 49 patients can be divided into two groups: cohort A includes 29 patients (22 families) 
with sufficient clinical data; and cohort B includes 20 patients (11 families) with incomplete data. Of 
the 49 cases, 24 are new. Twenty-five were previously published 6,7,12,14,17,19,24-29, and for 19 of these 
clinical data could be updated (Table 1). Patients originated from Australia, Belgium, Canada, 
Denmark, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, United Kingdom and 
United States.  
 
Genotype 
The 33 families harbor 29 unique and 2 recurrent variants [p.(Cys585Arg) and p.(Arg586*), each 
found in 2 families (Table 1, Fig. 1)]. A relatively large proportion of the cases are familial (nine out of 
21 index cases for whom inheritance could be established). Seven variants were copy number 
variations (CNVs): deletions of which six include genes besides RAD21. All CNVs where segregation 
could be investigated are de novo. Of the 24 unique sequence variants 13 are predicted be truncating 
(2 nonsense, 2 splice site and 9 frameshift variants), which are scattered throughout the gene. Three 
of the variants are in-frame deletions, two of which affect a single amino acid, while the 665 bp 
deletion includes the whole exon 13. Six out of eight unique missense variants are clustered at the 
functional domains of the protein. Some variants in cohort B may be recurrent but sufficient data are 




Evaluation of pathogenicity of RAD21 variants using molecular dynamic analyses 
For twelve intragenic variants (ten missense variants and two 3bp in frame deletions, from 
individuals in cohort A, B and Table S6) it was possible to carry out structural analysis, as their 
substituted residues are located in one of the domains for which 3D arrangement can be modeled 
(RAD21-SMC3 domain, RAD21-STAG domain and RAD21-SMC1A domain, Fig. 2; Figs. S2-3). 
Interactions between RAD21 and its binding partners are shown in Fig. S1.  
 
RAD21-SMC3 domain (residues 18-87) harboring Arg65Gln, and RAD21-STAG domain (residues 321-
392) harboring Ser345Pro, Pro355Leu and Pro376Arg: Substitution of Arg65 with Gln (Arg65Gln) is a 
semi-conservative variation that did not promote detectable structural or dynamic changes in the 
complex but could be partially disrupting a putative interaction with DNA. Ser345Pro variant impairs 
RAD21 and STAG1/2 interactions due to promotion of a de novo curved small alpha helix segment 
that binds to the pre-existing alpha helix, which separates from the surface of STAG2. No structural 
or dynamic effects of Pro355Leu or Pro367Arg on RAD21 itself could be observed. Nevertheless, 
Pro376Arg does promote formation of a new salt bridge between RAD21 and STAG2, which is 
predicted to cause over-stabilization of the interaction between the two proteins. 
 
RAD21-SMC1A domain (residues 543-628) harboring Gly575Ala, Cys585Arg, Arg586Gln, Gln592del, 
Phe600del, Leu603Pro, Ser618Gly, and Ala622Thr: Four of the eight variants in this domain 
(Cys585Arg; Arg586Gln; Gln592del; Leu603Pro) are predicted to cause a structural effect. Arg586Gln 
destabilizes the RAD21-SMC1A domain by loss of a salt bridge between Arg586 and Glu577, and the 
altered position of Glu577 adds an additional negative charge to the RAD21 surface of RAD21-
SMC1A. Cys585Arg has a similar effect, interacting with Glu583 and causing Arg586 to lose its contact 
with Glu577. The MD simulation shows that both Gln592del and Leu603Pro, but not Phe600del, 
affect positioning of SMC1A-Asn35 at the ATPase site 1 by changing the position of Lys605. 




Physical features: Individual CdLS scores and major and minor anomalies in cohort A are provided in 
Table S2-3. Clinical features of cohort A are compared to those of NIPBL and SMC1A cohorts in Table 
2 and illustrated in Fig. 3 and S4. Clinical information for cohort B is available in supplemental 
materials S5 and will not be discussed further in the text, as clinical data are limited. We mention 
data in the text only if not represented in the tables. 
All patients in cohort A (age range 0-61 years, median nine years, mean 18 years; 15 males) 
had CdLS scores of at least five, sufficient to warrant molecular genetic testing for CdLS. In about 60 
percent of index cases (13/21 index cases in which this was specified) CdLS was suspected prior to 
testing. There was no gender difference in CdLS scores. No RAD21 variant would have been missed 
by using the CdLS consensus criteria for molecular studies 9. Clinical scores of patients with CdLS 
suspected prior to testing (median 11.5; range 8-13) were higher than those not suspected to have 
CdLS (median 9.5; range 5-13). 
  
Cognition, development and behavior: Cognitive functioning, developmental milestones and 
behavioral functioning in the RAD21 group are attenuated compared to the NIPBL and SMC1A groups 
(Tables 3 and S4).  The majority of RAD21 patients (16/29, 55%) have normal or mildly impaired 
cognitive functioning (SMC1A group 32%; NIPBL group 7%) 20,21. In all three groups there is a trend 
towards more language-based problems than motor-based problems in development. Still, all RAD21 
patients aged 3 years and above were able to use some words. There was no correlation between 
the severity of cognitive impairment in RAD21 patients and presence of microcephaly (prenatal, 
postnatal, or both; data not shown).  
14/25 RAD21 patients (56%) with sufficiently available information on behavior had 
problems, mainly features of anxiety, ADHD, ASD, and obsessive-compulsive behavior. ASD related 




Genotype-phenotype comparisons in cohort A 
Microdeletions versus intragenic variants: There was a trend towards higher CdLS scores and more 
frequently impaired growth parameters in patients with microdeletions compared to those with 
intragenic variants, but no differences were apparent in frequency of major malformations or 
cognitive and behavioral problems. We refrained from statistical analyses as small numbers would 
make results too unreliable and less useful. Exostoses, related to EXT1 haploinsufficiency, likely 
caused the upper limb anomalies. 
 
Truncating versus non-truncating sequence variants: There was no difference in CdLS scores or 
growth parameters between individuals with truncating and those with non-truncating sequence 
variants (median 10; range 9-13 and median 9.5; range 5-12, respectively).  
 
Malformations and genotype: For 12/15 patients with intragenic variants and major malformations 
or health problems, the variant was located in a protein-binding domain (F2, F3a, F8, F9, F11a, F11b, 
F12, F14a, F14b, F16a, F17, F18). As numbers are small it remains uncertain whether this is truly an 
association. The types of major malformations did not differ. 
 
Intrafamilial variation: The intrafamilial variation can be considerable (Tables S1, S3-4; Fig. 3), 
especially in cognition and behavior. Through obvious ascertainment bias cognition is more 
frequently impaired in index cases. Several families include patients with ID and patients with 
apparently normal cognitive functioning. The intrafamilial variation cannot be explained by 






We report on RAD21 variants in 49 individuals, some with sufficient clinical data (cohort A), others 
with limited clinical data (cohort B). RAD21 variants are frequently familial, often unique, and 
without obvious hotspots for variants or microdeletions breakpoints, although missense variants 
tend to cluster around protein binding domains.  
 
RAD21 missense variants and their predicted effect on protein function  
Combining our data from structural and functional analysis with data from phenotype, database 
information and literature, nine out of twelve RAD21 missense variants that we modelled were 
demonstrated to be likely pathogenic. The structural and dynamic analyses indicate the Arg65Gln 
variant within the RAD21-SMC3 domain does not make it likely to be pathogenic. However, Arg65 is 
located in the close proximity of Tyr67, and altering the kinase/phosphatase recognition motif Arg-X-
Tyr around Tyr67 may affect the phosphorylation-based regulation of RAD21 30-33. In addition, a 
contact between the PDS5 protein and the RAD21-SMC3/SMC3-head complex is involved in the 
topological entrapment of DNA by cohesin 34. As Arg65 is located towards the solvent, Arg65Glu may 
impact the RAD21-PDS5 recognition and, thus, disturb their interaction.  
The interaction between RAD21 and STAG1/2 is crucial for the proper functioning of the 
cohesin complex 34, and both impairing (Ser345Pro) or over-stabilizing (Pro367Arg) variants within 
the RAD21-STAG domain are predicted to cause dysfunction of the complex, presumably through 
affecting the continuous cycle of formation and disengagement of the cohesin ring 35.  
The structural model of the RAD21-SMC1A domain rationalizes the key function of RAD21 in 
the ATPase reaction at the SMC1A/SMC3 head, which is pivotal to the opening of the cohesin ring 
and, thus, the cyclic process 35. The Cys585Arg and Arg586Gln variants destabilize the RAD21-SMC1A 
domain; and Gln592del and Leu603Pro (but not Phe600del) disturb the cyclic process through 
dislocation of Lys605. However, as the Phe600del variant does lead to a classical CdLS phenotype 
without variants in additional known CdLS genes, it does seem likely pathogenic. Unfortunately, the 
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crystal structure of RAD21 is not available for other domains or interacting partners such as WAPL 
and PDS5, but earlier molecular studies provide additional information for other missense variants.   
The importance of the regulation of interaction between RAD21-SMC1A and SMC1A/SMC3 
head is demonstrated by the several residues involved in phosphorylation and ubiquitination in the 
RAD21-SMC1A domain 31,32,36. Ala622 is positioned next to Thr623, a substrate for protein 
phosphorylation by PLK1 32,37. A pathogenic effect of variant Ala622Thr is supported by studies 
showing decreased bowel transit and loss of enteric neurons in zebrafish with Ala622Thr variants and 
patients with Mungan syndrome and CIPO (chronic intestinal pseudo-obstruction) 12. 
Two additional variants outside the domains that can be modeled, are likely to be 
pathogenic. As residue Thr461 is flanked by Ser residues (Ser459 and Ser466), both implicated in 
phosphorylation-regulated dissociation of cohesin from chromosome arms 32,38, it may modify the 
kinase/phosphatase recognition motif, thus affecting the protein behavior. Similarly, Phe6 is found 
close to Ser9, a phosphorylation site described in the human proteome 34,39.  The Phe6Val variant 
would modify the kinase/phosphatase recognition motif. 
 
Clinical phenotype 
Physical phenotype: RAD21 variants can lead to a CdLS phenotype (RAD21-CdLS). The (limited) 
available information of individuals from cohort B suggests that RAD21 variants can also lead to CIPO 
and (like one case in cohort A) holoprosencephaly and possibly schizophrenia, although in the latter 
the association may be a spurious coincidence. In Table S6 we describe several additional cases with 
phenotypes including sclerocornea and schizophrenia, in which pathogenicity of the RAD21 variant is 
debatable. Due to incomplete information it remains uncertain whether these individuals are also 
showing CdLS characteristics. Indeed, when we succeeded in obtaining further clinical information, 
several individuals turned out to show CdLS characteristics not mentioned in the publication (for 
instance in the family with CIPO). Additionally, one may speculate that phenotypes are also 




Comparison to phenotypes of NIPBL and SMC1A variants: In patients with sufficient clinical data 
available (cohort A) most features associated with CdLS are present. However, the prevalence of 
features is lower compared to those in the SMC1A and NIPBL cohort, and the degree of severity is 
typically less. Severe visual impairment and diaphragmatic hernias are rare in RAD21 patients, and 
feeding difficulties are uncommon. RAD21 patients less frequently have increased body hair 
(hirsutism, bushy eyebrows, low scalp hair lines), major limb malformations are not reported, and 
hands and feet are generally of normal size. Still, minor anomalies of hands and feet are common, 
such as fetal pads, abnormal flexion crease patterns, and camptodactyly. Patients with RAD21 
variants have generally less impaired growth at birth, and short stature and microcephaly develop 
postnatally. Prenatal microcephaly has been demonstrated to be a predictor of more severe 
cognitive impairment in CdLS in the pre-molecular era, 40 but this does not hold for RAD21 patients. 
Frequency and severity of congenital heart defects is similar to those in the NIPBL and SMC1A 
cohorts. Gastro-esophageal reflux is similar in frequency but in RAD21 it is typically mild and 
restricted to early childhood. No RAD21 patients exhibit a Rett-like phenotype as can occur in SMC1A 
patients 20. The CdLS score remains a reliable tool, and the present study does not call for adjustment 
of the diagnostic advice from the CdLS guidelines 9.  
 Unusual anomalies in the RAD21 cases are vertebral anomalies (clefts and hemivertebrae). 
There is a single individual with a NIPBL variant and Klippel-Feil anomaly (personal observation RCH), 
and upper cervical spine malformations have been reported in other patients with NIPBL variants as 
well 41. Malformations of structures derived from the embryonic foregut are relatively frequent in 
RAD21 patients and have only rarely been described in CdLS 42-44. Holoprosencephaly spectrum 
anomalies have been linked to several cohesin genes 14, including RAD21, although in one individual 
this remains uncertain (Table S6). The prevalence of holoprosencephaly spectrum in RAD21-CdLS 
must remain uncertain as brain MRIs are typically not indicated in individuals with CdLS due to the 




Development, cognition and behavior: Most data on cognition and behavior in the present cohort 
are based on subjective information provided by physicians and not on formal testing. Therefore, 
reliability remains uncertain. Still, all data point to a lower prevalence and decreased severity of ID in 
RAD21 patients compared to NIPBL and SMC1A groups: developmental milestones are more 
frequently attained, cognitive level is estimated higher, aggression less and autism less frequent. SIB, 
a hallmark of CdLS in general 9, is infrequent in RAD21 individuals.  
Also, if an IQ is normal, subtle difficulties in neuropsychological domains known to be 
affected in CdLS 9 may influence cognitive performance. Periodic formal screening for 
neuropsychological and behavioral problems is still warranted in all individuals with RAD21 variants, 
to allow for early recognition of problems and access to relevant support systems. In addition, formal 
(in-person) assessments can prevent misdiagnoses, such as autism, by putting behavioral 
characteristics into perspective of the developmental level of patients 21. 
 
Natural history: The natural history data from the present study indicate that pregnancies and birth 
tend to progress normally, prenatal growth retardation being present in a small minority. About half 
of the patients have congenital anomalies (cleft palate; cardiac anomalies). Major limb defects have 
not been found; diaphragmatic hernia, anal atresia or choanal atresia occur occasionally. Patients 
have typically mild facial dysmorphisms, no small hands or feet, and increased body hair is less 
apparent compared to SMC1A and NIPBL patients. The clinical diagnosis of CdLS may therefore be 
difficult.  
Neonatal feeding is usually not problematic. Reflux is common but not severe. Typical 
development is somewhat slow, mainly in speech development, and physical therapy or speech 
therapy may be indicated. As they grow up, children only occasionally develop new medical 
problems. Half of the children show a progressive but still mild growth delay in head circumference 
and height. Vision is mostly normal; hearing loss is found in a third of individuals and may require 
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hearing devices. Most of the patients are able to attend regular education or education for children 
with mild cognitive disabilities. Most have some behavioral problems (mainly anxiety, ADHD or ASD) 
of limited severity, and aggression and SIB are uncommon. Not uncommonly, RAD21 patients are 
able to start a family, and some are only diagnosed when more severely affected offspring is 
recognized. 
 
Genotype-phenotype associations: Patients with haploinsufficiency for RAD21 due to microdeletions 
or truncating variants do not differ markedly from those with missense variants, and nonsense 
mediated decay is not apparent. It remains uncertain whether duplication of the whole gene can lead 
to a CdLS phenotype, as demonstrated for duplications in STAG2 and SMC1A 45,46, as all duplications 
we retrieved, were either including several other genes or pathogenicity could not be confirmed. No 
fully intragenic duplication is known to us. Small duplications have also been detected in apparently 
healthy controls (unpublished observations J. Howe). 
 In general, protein studies combined with a detailed phenotype allow often, but not always, 
to probe for RAD21 dysfunction in patients with variants of doubtful meaning. The phenotype in 
individuals with RAD21 variants is not only determined by the variant itself but potentially also by 
other factors: 1) variable expression of cohesin subunits and/or binding partners in different tissues; 
2) variable formation of isoforms in different tissues; 3) modifying genes, especially of the cohesin 
complex 6; 4) Epigenetic factors such as methylation and gene silencing 47. Exact phenotypic 
consequences, if any, of each of the above are unknown.  
In counseling of families with RAD21 variants, the relatively high frequency of familial 
occurrence and marked intrafamilial and interfamilial variability should be considered. Parental 
testing is warranted, even if signs or symptoms are apparently absent in parents, and standard 
testing of parents may further broaden the phenotype of RAD21 variants. We suggest a cautious use 
of data on variants in molecular databases, as due to the extremely variable and sometimes very mild 
phenotype wrong conclusions may be drawn in classifying the variants. In case of a CdLS phenotype 
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and detection of a VUS in RAD21, we recommend testing for variants in other CdLS associated genes 
and eventually carry out ’open’ exome/genome sequencing. 
 
Limitations: Although we used a broad search strategy and the present RAD21 cohort is the largest 
reported thus far, numbers are still small, and these preclude further statistical analyses. We did not 
consider variants from ClinVar or Decipher that were reportedly (likely) benign, but we expect that 
these may contain some pathogenic variants discarded based on an overlooked (mild) phenotype. 
Furthermore, many variants are reported with insufficient clinical data preventing such patients to be 
included in the present series. Especially morphological data are often missing, and we stress the 
importance of the use of the CdLS consensus data in evaluating individuals with variants in cohesin 
genes 9. Next generation sequencing based technologies such as gene panels or ‘open’ 
exome/genome sequencing remains to be introduced in many countries, and we expect 
identification of many additional patients with pathogenic RAD21 variants as clinical recognition may 
be difficult. Lastly, we may have an acquisition bias due to involvement of specialists in CdLS, causing 
an overrepresentation of individuals with a CdLS phenotype.  
 
Future: The present results demonstrate that more information on larger groups of individuals with 
RAD21 variants is needed to determine the complete phenotypic spectrum. CdLS characteristics such 
as sleep disturbances and autonomic dysfunctions in individuals with RAD21 variants are still largely 
unknown. A specific issue that needs attention is the risk to develop cancer (not reported to date in 
RAD21 patients) 17,19. We call also for more detailed study of cognitive, behavioral and psychiatric 
phenotypes, as these are of utmost importance in clinical care. Molecular and cellular mechanisms 
underlying cognitive problems are unclear, although cohesin-mediated 3D-organization of the 
genome suggests a role for neuronal plasticity 48. Studying RAD21 and other cohesin components in 
this process could contribute to the search for targeted influencing of cognition and especially 
behavior in CdLS. Effects of RAD21 variants on cellular functioning and relationships between 
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genotype and phenotype may be elucidated further by studying genome-wide methylation patterns 
(episignature), which have been shown to be altered in CdLS 49. This may explain presently 
unexpected discrepancies between genotype and phenotype, and even allow for establishing 







Patients were gathered using a combination of literature and database search and network inquiries 
(see Supporting Information). A dedicated questionnaire was used to gather clinical, molecular, 
cognitive and behavioral data. If allowed by the family clinical pictures were gathered for scoring of 
facial characteristics by the senior author (RCH). If no clinical pictures were available to us (n=3 in 
cohort A) the clinician-reported description of facial characteristics was accepted. The CdLS clinical 
score (reflecting the similarity of clinical features to those in classical CdLS) was computed using 
cardinal features (2 points each) and suggestive features (1 point each) according to Kline and co-
authors 9. 
Information on cognitive functioning and behavioral problems was derived from physician 
reported data, if possible substantiated with results of formal testing. For the CdLS clinical score, 
minor criterion “ID or global DD” was scored positive if ID or global DD (global developmental delay; 
a combination of delay in at least 2 developmental domains) was present, at any age. Elsewhere in 
the manuscript, cognitive functioning has been classified into categories based on DSM-5.  
To compare the RAD21 phenotype to CdLS patients with variants in other genes, clinical data 
were obtained from existing NIPBL and SMC1A cohorts 20,21, to which we added further information if 
needed. For comparison of features of ASD and aggression in NIPBL patients, we derived information 
from the UK cohort 22. For the item ‘autistic like behavior’, we compared with scores from the Social 
Communication Questionnaire (number above cut-off for ASD); for the item ‘aggression’ with 
presence of verbal aggression, physical aggression or property destruction on the Challenging 
Behavior Questionnaire; and for ‘obsessive-compulsive behavior’ with the number of patients with 
one or more items of the compulsive behavior subscale of the Repetitive Behavior Questionnaire 
above clinical cutoff. 
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Based on availability of clinical data, we composed two cohorts: cohort A with sufficient 
clinical data available on all cardinal CdLS features, and cohort B with incomplete clinical data. We 
provide an overview of excluded cases in Supporting Information Table S6. 
 
Molecular studies 
Among the 29 patients (22 index) of cohort A, a clinical diagnosis of CdLS was suspected in 13 index 
cases, which allowed detection of RAD21 variants using array comparative genomic hybridization 
(CGH, (n=1), Sanger sequencing (n=6), ‘whole’ exome sequencing (WES, n=2), or targeted exome 
sequencing searching for variants in genes that can cause intellectual disability (ID-WES, n=4). 
Confirmation by Sanger sequencing of an exome result was only performed if the coverage of the 
exome was thought to be of insufficient quality. The other nine index cases were detected through 
Sanger sequencing of a series of candidate genes after excluding a clinical diagnosis (KBG syndrome, 
n=1), or after WES (n=2), ID-WES (n=3), or array CGH or SNP array (n=3). All molecular studies were 
performed for diagnostic reasons, following the various national regulations, and for none of the 
patients studies were performed because of the current research. For describing the variants coding 
DNA reference sequence NM_006265.2(RAD21_v001) is used.  
 
Structure modeling of RAD21 variants 
A set of three wild-type and twelve variant protein models was generated through standard 
homology modeling procedures using the SWISS-MODEL server (http://swissmodel.expasy.org; see 
Supporting Information). These were used to study the structural effects of the missense variants 
located in the protein domains in contact with SMC3 (RAD21 N-terminus; RAD21-SMC3), STAG1/2 
(RAD21-STAG) or SMC1A (RAD21 C-terminus, RAD21-SMC1A). 
 
Molecular dynamics simulations 
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To analyze the putative effect of variants on the RAD21 structure, the behavior of the twelve variant 
proteins were compared to that of wild type models by free molecular dynamics (MD) simulation for 
60-100 nanoseconds (ns) (see Supporting Information). Movements during the trajectories were 
continuously measured by root-mean square deviation (RMSD) of atomic positions. Large variations 
of RMSD values indicate notable distortions of protein structure due to the abnormal amino acid 
variant. RAD21 domains were modeled in complex with the accompanying proteins, to facilitate 
functional evaluation of variants along the MD trajectories. 
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Figure 1 A-B. Presently reported RAD21 variants. 1a. RAD21 (horizontal bar) has three binding domains: SMC3 (p.1–103), STAG1/2 (p.362–403) and SMC1A 
(p.558–628). Sizes of the binding domains are not shown to scale. Truncating RAD21 variants are shown above, and missense mutations and in-frame 
deletions are shown below the protein representation. Variants for which protein modelling is available, are marked in bold. F: family number. The 
horizontal black line represents the inframe deletion p.(Asp541_Gln568del). ClinVar, variants which are reported in the ClinVar database and could be 







Figure 2 A-F. Structural modeling of RAD21-SMC1A domain bound to the head domain of SMC1A/SMC3 complex.  
A. Model for the RAD21-SMC1A domain (residues 543-628, green) associated to the head domains of SMC1A (grey) and SMC3 (orange), close to the ATP 
molecule in ATPase site 1 (ATP-1) of the SMC1A/SMC3 dimer. Position of mutated residues (Gly575, Cys585, Arg586, Gln592, Phe600, Leu603, Ser6018 and 
Ala622) is indicated as red spheres. Locations of other important residues (Lys573, Gly575, Lys605, and Thr623) are indicated. Residue Cys585 is located next 
to residue Arg586. Residue Arg586 interacts through a salt bridge with RAD21 residue Glu577, stabilizing RAD21-SMC1A structure. Three mutated residues 
(Gln592, Phe600, Leu603) are located in the same alpha helix as key residue Lys605, predicted to maintain the correct positioning of SMC1A-Asn35 at 
ATPase site 1, putting it into contact with a catalytic water molecule and, thus, allowing progression of the ATPase reaction, pivotal to opening of the 
cohesin ring and the cyclic process 35. Variants Ser618Gly and Ala622Thr do not cause structural alterations. 
B. Root mean square deviation (RMSD, in Angstroms) of modeled structures (WT, wild-type, blue line; Gly575Ala, red; Cys585Arg, light purple; Arg586Gln, 
dark green; Gln592del, light blue; Phe600del, orange; Leu603Pro, cyan; Ser618Gly, dark purple; Ala622Thr, light green. No relevant differences in RMSD 
values demonstrable in the trajectories of the mutated models when compared with wild-type model and with one another.  
C. Variant Cys585Arg causes the adjacent Arg586 to lose interaction with Glu577, and both the Arg586 and Glu577 residues change their position in the 
mutant protein by pointing towards the solvent, which modifies the distribution of charges in the surface of RAD21-SMC1A, while the new Arg585 residue is 
stabilized in a novel interaction with Glu583. 
D. Model for variant Gln592del after 100 ns of MD. New positions of Arg590, Lys591 and Lys605 due to the absence of Gln592 are indicated. Deletion of 
Gln592 residue causes adjacent Lys591 to be located in the same position as the missing amino acid. This situation promotes a conformational change in the 
alpha helix, causing the Lys605, which is placed in the same alpha helix, to move away from site 1 of the ATPase.  
E. Model for variant Phe600del (green) compared to wild-type model (pink) after 100 ns of MD. Despite the local rearrangement in the alpha helix, 
distortions of the alpha helix are not relevant as residue Leu601 is placed spatially in the position equivalent to the deleted Phe600 during the MD 
trajectory, allowing Lys605 to remain in the same position. 
F. Structure of wild-type RAD21-SMC1A (left) and variant Leu603Pro (right) models after 100 ns of MD. Presence of mutated Pro603 instead of wild-type 
Leu603 promotes a local change in the bending angle of the alpha helix in which it is located, resulting in a conformational change in the alpha helix that 

































Figure 3: Clinical phenotype in RAD21 patients. Anterior-posterior facial views. 
F: Family identification number, y: age in years. Family numbers correspond to family numbers in the tables. Ages are indicated below each picture.  
Intrafamilial variability is illustrated by comparison of facial morphology between the members of family F6 and of family F16. Interfamilial variability is 
illustrated by comparison of facial morphology between patients F15 and F16a/b who harbor the p.(Arg586*) variant. Pictures of members of F6 and of F17 




Table 1. Molecular findings of the presently reported series of individuals with RAD21 variants. Cohort A: detailed information available, sufficient to score 
CdLS score; cohort B: insufficient data available to score CdLS score.  
 
PID Reference CdLS 
score† 




F1 Martinez 2017, 
(updated) 
9 exon 2 c.68G>A p.(Trp23*) Nonsense de novo 
F2 unpublished ≥7 exon 2 c.194G>A p.(Arg65Gln) Missense‡ 
 
F3a Ansari 2014 P1, 
(updated) 
≥10 intron 3 c.274+1G>A 
 
Splice site familial (paternal) 
F4 Minor 2014 P2, 
(updated) 
12 exon 6 c.592_593dupAG p.(Ser198Argfs*6) Frameshift 
 
F5 unpublished 9 exon 6 c.617_620del  p.(Ile206Thrfs*3) Frameshift de novo 
F6a Boyle 2017 IV.16, 
(updated) 
12 exon 7 c.704delG p.(Ser235Ilefs*19) Frameshift familial (maternal) 
F6b Boyle 2017 III.1, 
(updated) 
10 exon 7 c.704delG p.(Ser235Ilefs*19) Frameshift familial (parents not 
tested) 
F6c Boyle 2017 III.2, 
(updated) 
9 exon 7 c.704delG p.(Ser235Ilefs*19) Frameshift familial (parents not 
tested) 
F6d Boyle 2017 III.5, 
(updated) 
9 exon 7 c.704delG p.(Ser235Ilefs*19) Frameshift familial (parents not 
tested) 
F6e  unpublished 12 exon 7 c.704delG p.(Ser235Ilefs*19) Frameshift familial (maternal) 
F7 Dorval 2019 ≥11 exon 9 c.943_946del  p.(Glu315Glnfs*9) Frameshift de novo 
F8 Deardorff 2012 P5 ≥10 exon 9 c.1127C>G p.(Pro376Arg) Missense‡ de novo 
F9 Kruszka 2019 P14 
(updated)  
13 exon 10 c.1217_1224del p.(Lys406Argfs*4) Frameshift de novo 
F10 unpublished 10 exon 11 c.1382C>T p.(Thr461Ile) Missense familial (paternal) 
F11a Minor 2014 P1, 
(updated) 
8 exon 13 c.1621-
388_1704+193del 
p.(Asp541_Gln568del) Inframe deletion  familial (maternal) 
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F11b Minor 2014 mother P1 
(updated) 
≥5 exon 13 c.1621-
388_1704+193del 
p.(Asp541_Gln568del) 665 bp inframe 
deletion  
 
F12 unpublished 13 exon 13 c.1635del p.(Gly547Alafs*65)  Frameshift de novo 
F13 Deardorff 2012, P6 ≥12 exon 14 c.1753T>C  p.(Cys585Arg) Missense‡ de novo 
F14a unpublished 12 exon 14 c.1753T>C p.(Cys585Arg) Missense‡  familial (parents not 
tested) 
F14b unpublished ≥10 exon 14 c.1753T>C p.(Cys585Arg) Missense  familial (parents not 
tested) 
F15 unpublished ≥12 exon 14 c.1756C>T p.(Arg586*) Nonsense 
 
F16a unpublished 10 exon 14 c.1756C>T p.(Arg586*) Nonsense familial (paternal) 
F16b father, unpublished ≥10 exon 14 c.1756C>T p.(Arg586*) Nonsense 
 
F17 Gudmunsson 2019, 
updated 
8 exon 14 c.1774_1776del p.(Gln592del) Inframe deletion‡  de novo 
F18 unpublished 9 exon 14 c.1800_1802del p.(Phe600del) Inframe deletion‡ 
 
F19 Deardorff 2012 P4 ≥12 whole gene arr[hg19] 8q23.3q24.11(116880827-
118875305)x1 
2 Mb deletion 
 
F20 unpublished ≥12 whole gene arr[hg19] 8q23.3q24.11(116915114-
119171074)x1  
2.3 Mb deletion de novo 
F21 Deardorff 2012 P2, 
McBrein 2008 
≥12 whole gene arr[hg19] 8q23.3q24.12(117571728-
119260904)x1 
1.7 Mb deletion de novo 
F22 unpublished 12 exons 1-9 arr[hg19] 8q24.11(117866471-117893495)x1               27 kb deletion  
COHORT B 
F3b Ansari 2014, (updated) 
 
intron 3 c.274+1G>A n/a Splice site 
 
F23 Decipher 271431 
 
exon 2 c.16T>G p.(Phe6Val) Missense de novo 
F24 unpublished 
 
exon 2 c.85delinsCCT p.(Lys29Profs*10) Frameshift 
 
F25a Decipher 272901 
 
exon 9 c.951del p.(Ala318Profs*7) Frameshift familial (paternal) 
F25b Decipher 272901 
father 
 
exon 9 c.951del p.(Ala318Profs*7) Frameshift 
 
F26 Decipher 275402 
 
exon 9 c.1033T>C p.(Ser345Pro) Missense‡ de novo 
F27a Yuan 2018 P2, 
(updated) 
 
intron 10 c.1161+1G>A  
 
Splice site familial (maternal) 
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F27b Yuan 2018 mother P2, 
(updated) 
 




F28a Kruszka P12/Yuan P1, 
(updated) 
 
exon 12 c.1550dupC p.(Glu518Argfs*19) Frameshift familial (paternal) 
F28b Kruszka P12 
father/Yuan P1 Father, 
(updated) 
 
exon 12 c.1550dupC p.(Glu518Argfs*19) Frameshift 
 
F29 Lee 2014 P76 
 
exon 14 c.1808T>C p.(Leu603Pro) Missense‡ de novo 
F30a Bonora 2015 IV.9, 
(updated) 
 
exon 14 c.[1864G>A];[1864G>A]  p.(Ala622Thr) Missense‡ familial (both 
parents) 
F30b Bonora 2015 IV.10, 
(updated) 
 
exon 14 c.[1864G>A];[1864G>A]  p.(Ala622Thr) Missense‡ familial (both 
parents) 
F30c Bonora 2015 IV.11, 
(updated) 
 




exon 14 c.[1864G>A] p.(Ala622Thr) Missense‡ familial (nos) 
F30e unpublished 
 
exon 14 c.[1864G>A] p.(Ala622Thr) Missense‡ familial (nos) 
F30f unpublished 
 
exon 14 c.[1864G>A] p.(Ala622Thr) Missense‡ familial (nos) 
F31 ClinVar 
 
Whole gene arr[hg19] 8q23.3-24.11(116902507-
118942698)x1 




F32 ClinVar  Whole gene  
arr[hg19] 8q23.3-24.11(117509968-
118391406)x1  










†Based on 9;  ≥ defines at least (minor criteria missing) Score <4 is insufficient to indicate molecular testing for CdLS; score 4-8 indicates molecular 
testing for CdLS indicated; score 9-10 indicates non-classic CdLS; score 11 or higher indicates classic CdLS ; ‡Variants investigated with protein modelling 
F: family number; P: patient number in the respective publication; nos: not otherwise specified; VUS, variant of unknown significance  
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Table 2. Comparison of clinical characteristics of present series of individuals with RAD21 variants with sufficient clinical data (cohort A) with those in 



















Sex (Male/Female)  15/14 52/48 14/37 27/73 34/33 51/49 
Familial mutation  5/12 42 4/47 9 n/a n/a 
Length at birth <-2SD HP:0003561 2/18 22 9/31 28 32/43 74 
Weight at birth <-2SD HP:0001511 4/22 18 11/41 27 29/43 67 
Prenatal head circumference <-2SD HP:0000252 7/16 44 8/24 33 39/43 91 
Postnatal height <-2SD HP:0008897 10/27 37 24/38 63 37/43 86 
Postnatal weight <-2SD HP:0004325 3/26 12 14/37 38 39/43 91 
Postnatal head circumference <-
2SD 
HP:0000252 16/28 57 23/36 64 54/62 87 
Brachycephaly HP:0000248 8/19 42 17/42 40 44/67 66 
Low anterior/posterior hairline HP:0000294/HP:000216
2 
14/23 61 30/43 70 57/67 85 
Arched eyebrows HP:0002553 18/27 67 32/44 73 54/67 81 
Synophrys HP:0000664 19/28 68 37/46 80 61/67 91 
Thick eyebrows HP:0000574 20/24 83 37/46 80 61/67 91 
Long eyelashes HP:0000527 21/26 81 38/45 84 65/67 97 
Concave nasal ridge HP:0011120 24/29 83 20/43 47 57/67 85 
Upturned nasal tip HP:0000463 19/27 70 26/46 57 58/67 87 
Short nose HP:0003196 23/26 88 26/46 57 58/67 87 
Long and/or smooth philtrum HP:0000343/HP:000031
9 
26/29 90 27/43 63 54/67 81 
Thin upper lip vermillion HP:0000219 23/29 79 33/44 75 22/24 92 
Thin lips, downturned corners 
mouth 
HP:0002714 16/27 59 33/46 72 23/24 96 
34 
 
Highly arched palate HP:0000218 8/22 36 11/37 30 35/67 52 




6/25 24 10/45 22 20/67 30 
Widely spaced or absent teeth HP:0000687/HP:000634
9 
2/20 10 13/44 30 18/23 78 
Micrognathia HP:0000347 8/23 35 18/45 40 50/67 75 
Low-set and/or malformed ears HP:0000369/HP:000037
7 
14/26 54 18/45 40 45/67 67 
Major limb malformation HP:0001180/HP:000977
6 
0/29 0 0/49 0 17/67 25 
Small hands HP:0200055 5/27 19 32/45 71 53/63 84 
Proximally placed thumb HP:0009623 6/18 33 18/44 41 11/20 55 
Clinodactyly 5th finger HP:0004209 13/24 54 21/45 47 42/63 67 
Short 5th finger HP:0009237 23/28 82 21/45 47 42/63 67 
Syndactyly hands HP:0006101 1/19 5 1/37 3 4/63 6 





11/24 46 2/40 5 20/34 59 
Small feet HP:0001773 3/27 11 29/44 66 65/67 97 
Syndactyly 2nd-3rd toes HP:0004691 4/24 17 13/46 28 21/66 32 
Scoliosis HP:0002650 2/20 10 4/40 10 1/42 2 
Hip dislocation or dysplasia HP:0002827/HP:000138
5 
2/19 11 2/40 5 
  
Ptosis HP:0000508 11/26 42 4/40 10 8/42 19 
Visual impairment HP:0000505 0/24 0 20/38 53 29/66 44 
Myopia ≥ -6.00 D HP:0011003 ≤2/24‡ ≤8 11/40 28 6/40 15 
Hearing loss HP:0000365 8/24 33 16/39 41 43/66 65 
Seizures HP:0001250 2/22 9 20/44 45 10/66 15 
Cutis marmorata HP:0000965 3/23 13 19/44 43 27/43 63 
Hirsutism HP:0001007 10/26 38 37/47 79 37/43 86 
35 
 
CNS major and minor 
malformations (MRI Brain) 
HP:0012443 2/5 40 5/43 12 
  
Heart (major and minor)  HP:0001627 9/23 39 13/44 30 18/66 27 
Major malformation of gut HP:0012718 4/30 13 3/44 7 6/24 25 
Diaphragmatic hernia HP:0000776 1/30 3 1/40 3 6/24 25 
Gastroesophageal reflux disease HP:0002020 13/25 52 25/42 60 47/66 71 
Genitourinary system major§ HP:0000119 1/20 5 4/42 10 0/67 0 
Genitourinary system minor HP:0000119 8/23 35 9/40 23 46/67 69 
HPO ID, Human phenotype ontology identifier; CNS, central nervous system; † Only features which could be compared across at least two cohorts are 
presented. Full clinical description with individual data are presented in supplementary Table S3;  ‡2 others among the 24cases have myopia but 
unspecified severity; § Uni/bilateral renal anomalies. 
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Table 3. Cognitive and behavioral characteristics of individuals with RAD21 variants with sufficient clinical 
data (cohort A) with those in individuals with SMC1A and NIPBL variants (adapted from 20-22). 
 
RAD21 (n=29) SMC1A (n= 51) NIPBL (n=67) 
 N pos/ 
N total 
% N pos/ 
N total 
% N pos/ 
N total 
% 
Cognitive functioning†             
Normal cognition 3/29‡  10 3/28 11 0/58 0 
Mild disability (HP:0001256) 13/29 45 6/28 21 4/58 7 
Moderate disability (HP:0002342) 4/29§ 14 9/28 32 16/58 28 
Severe disability (HP:0010864) 0/29 0 6/28 21 27/58 47 
Profound disability (HP:0002187) 0/29 0 4/28 14 11/58 19 
Disability present, severity unspecified 
(HP:0001249) 
2/29 7 
    
Developmental problems, too young to 
determine reliably cognitive functioning 
(HP:0012759) 
7/29 24 
    
Developmental milestones¶             





























































































Delay on one or more milestone 12/16 75 18/20 90 51/52 98 
Behavior‡‡             
Attention deficit disorder +/- hyperactivity 8/23 35 
    
Obsessive-compulsive behavior 6/19 32 10/26¶¶ 38 
  
Anxiety 10/19 53 
    
Constant roaming 3/15 20 
    
Aggression 1/16 6 
  
12/15¶¶ 80 
Self-injurious behavior 1/18 6 11/31 35 47/61 77 
Extreme shyness or withdrawal 0/17 0 
    
Autistic-like features 7/20 35 18/31¶¶ 56 9/13¶¶ 69 
One or more behavioral domains affected 14/25 56         
HP, Human phenotype ontology identifier; †RAD21, 8 formal test results, others physician reported data. Equivalent 
HP is shown between brackets; ‡ includes 2 adults with learning disabilities but reported normal cognitive functioning; 
§ including 2 moderate/severe; ¶Only scored if child was older than target age; ††percentage of individuals that attain 
the milestone before age 3 years; ‡‡RAD21: 5 formal test results, others physician reported data; §§ Including 18 
patients that attained the milestone late, but age unknown; ¶¶based on formal testing.  
